category:watercooler
How much are people paying for GLP1s? (2024/11)
We take another look at reports of what people are paying for GLP1s with/without insurance and everywhere in between.
GLP1.Guide Staff
Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
category:factsheet
A list of FDA approved GLP1s
A list of FDA approved GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc), for easy reference.
category:side-effects
Anxiety and suicidal thoughts after stopping GLP1s?
Reports of anxiety and suicidal reports have been reported for people after *stopping* use of GLP1s. We dig in, and weight the FDA's comments.
government
Biden-Harris administration keen on GLP1s
The outgoing Biden-Harris admin puts out a proposal on widening access to GLP1s, which we hope the incoming Trump admin will also adopt.
category:watercooler
Weight loss "stalling" on GLP1s?
What happens when weight loss stalls on GLP1s? We check around the GLP1 community to see what people have figured out.
country:uk
The UK's bet on GLP1
A look at the UK's growing evaluation and use of GLP1 receptor agonists -- Ozempic, Mounjaroy, Wegovy, Zepbound and more.
research
Research on GLP1 Signaling in the brain
How does GLP1 signal the brain? We take a look at related research to try and learn more.
GLP1s and Osteoarthritis
Newly published research explores the link between Osteoarthritis and GLP1s -- positive results that are somewhat predictable.
category:news
Viking Therapeutic's new GLP1 impresses at ObesityWeek 2024
At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.
category:side-effects
Semaglutide's link to blinding disease (NAION)
We explore the link between blinding disease/vision loss and Semaglutide, as reported by medical research.
category:factsheet
Patent expirations for GLP1 Receptor Agonists
How long will we have to wait for generic versions of GLP1 drugs? We take a look at patent expiry dates for the most popular brands & GLP1 formulations.
category:news
FDA reconsidering Tirzepatide shortage list removal
After legal action by a group of compounders, the FDA is reviewing their removal of Tirzepatide (Mounjaro, Zepbound) from the shortage list.
category:news
Compounders sue FDA over Tirzepatide shortage changes
Compounders sue FDA for removing Eli Lilly's weight loss drug from the shortage list. Does the case have legs?
category:news
Why the Tirzepatide shortage ending might be bad news.
Bad news that sounds like good news: FDA ends shortage Eli Lilly's GLP-1 (Tirzepatide). We'll tell you why that's bad news.
category:news
GLP1s and Sleep Apnea
GLP1s (in particular Tirzepatide, created by Eli Lilly) have positive effects on Sleep Apnea
Habener, Mosjov and Knudsen win the Lasker award
The current GLP1 receptor agonist boom was made possible by the work of Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov.